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Abstract: In the rare case of a male patient presenting with a
combined small cell lung carcinoma (SCLC), large cell neuroendo-
crine carcinoma and adenocarcinoma, we used whole genome anal-
ysis by tiling-path array comparative genomic hybridization to
evaluate the clonal relationship between nodules. In two areas of
SCLC distinguishable by divergent neuroendocrine marker expres-
sion (CD56 and chromogranin-A), the presence of identical genomic
breakpoints and rearrangements indicated a common origin, with the
presence of additional distinct genomic alterations in these two
components indicating diverging clonal evolution. The absence of
shared genome alteration features for the adenocarcinoma and large
cell neuroendocrine carcinoma components suggested that these
tumors evolved independently from the SCLC. Taken together, the
array comparative genomic hybridization data demonstrate the de-
velopment and evolution of three independent primary lung cancers
in close proximity to each other to form a combined carcinoma.
Application of whole genome analysis shows the potential utility of
high resolution molecular tools in resolving the origin and delineat-
ing the clonal relationships of a tumor that contains heterogeneous
histologic components leading to an ambiguous histogenesis.
Key Words: Combined carcinoma, Breakpoint, Clonal, Array
CGH, LCNEC, SCLC.
(J Thorac Oncol. 2009;4: 227–239)
Because pulmonary metastases and multiple independentprimary tumors will be staged and managed differently,
determining the clonal relationship between multiple tumors
found in the same patient is essential. In clinical practice, the
relationship between such tumors may be defined by their
location and morphologic features.1 Unfortunately, his-
topathological criteria may not be adequate to determine
clonality with certainty. Tumors that exhibit similar histology
may not easily be defined as independent or related. More-
over, it is possible that different cancer subtypes arise from
the same progenitor cell, suggesting that it may not be
appropriate to use a default diagnosis of multiple primary
tumors where subtypes differ.2
A small cell lung carcinoma (SCLC) that contains
histologically distinct areas of one or more types of non-small
cell carcinoma is called a combined tumor. The non-small
cell component could be adenocarcinoma (AC), squamous
carcinoma, large cell carcinoma or large cell neuroendocrine
carcinoma (LCNEC). Although combined tumors are rare,
multiple synchronous and metachronous lung cancers are
encountered more frequently, especially with the current use
of highly sensitive spiral computed tomography (CT) for
early detection of lung cancer. Clonal relationships between
components of combined tumors involving SCLC have been
investigated using techniques that assess allelic genomic
imbalances and/or oncogenic mutations commonly found in
lung cancer.3–6 However, these techniques can only assess
imbalanced losses at a limited number of chromosomal loci,
providing very low resolutions of genomic alteration evalu-
ation that occur within the tumor cell genome.
Characterizing the boundaries of genomic alteration for
these combined tumors may provide some insight into the
origin and clonal evolution of multiple histologically distinct
tumors. Genomic alterations shared among different histo-
logic components may represent features that characterize the
cancer “stem/progenitor” cells of the tumor. These genomic
changes could possibly account for shared tumor phenotype,
such as resistance, and may represent what should be the true
targets of therapy.
The advent of high-resolution genome profiling tech-
nologies represents a powerful tool for defining the clonal
relationship between tumors arising in a single patient. Re-
cent reports have demonstrated the utility of array compara-
tive genomic hybridization (CGH) in establishing the rela-
tionship between tumors in such cases, including a survey of
multiple lung tumors from three different patients.7 In this
report, we have applied a similar strategy to defining the
relationship between a combined lung cancer with at least
three histologic components: SCLC, AC, and LCNEC. In
addition, the SCLC demonstrated two components that are
distinguishable by their divergent immunohistochemistry
phenotypes. Based on a tiling-path platform comprised of
overlapping elements that span the human genome, we have
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fine mapped boundaries for segmental DNA alterations in
each of these component tumors, using the presence of
identical genomic breakpoints between tumors as signature
markers for shared clonal origin.
CASE REPORT
A 71-year-old man developed pain in his neck, leading
to chest radiograph and CT studies that showed a right upper
lobe lung mass. A CT-guided fine needle aspiration biopsy
showed non-small cell lung cancer. He smoked 1 to 1.5 packs
per day for 27 years until quitting 14 years before presenta-
tion. Extrathoracic staging investigation with abdominal ul-
trasound showed multiple echogenic nodules in the liver, but
similar findings were noted 18 months earlier and CT scan
evaluation of one of these lesions was felt to be a hemangi-
oma. The patient was also noted to have a right adrenal
myelolipoma both 18 months earlier and at staging investi-
gation. Although a bone scan showed a small focus of activity
in the midcervical spine on the left side, it was felt to be
nonspecific and head CT was normal. Following negative
FIGURE 1. Microscopic features of
a combined carcinoma. A, Border-
ing area of large cell neuroendo-
crine carcinoma (LCNEC) and ade-
nocarcinoma components. B,
Higher magnification of LCNEC
showing focal necrosis. C, CD56
membranous immunostaining for
LCNEC tumor cells. D, Adenocarci-
noma component with papillary
and acinar features. E–H, Small cell
carcinoma component of com-
bined tumor with two areas distin-
guished by their expression of
CD56 and chromogranin-A (Chr).
SC1 area showed negative or focal
chromogranin-A staining (H) and
strong membranous CD56 staining
(G), while SC2 was chromogra-
nin-A positive (H) but CD56 nega-
tive (G). (Magnifications: (A) and
(E), 25; (B), (C), and (F), 200;
(D), 100; (A), (B), (C), (D), (F):
hematoxylin and eosin; (C), (G),
(H): immunohistochemistry).
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frozen section evaluation of mediastinal lymph node biopsies,
a right upper lobe lobectomy was performed. The patient’s
postoperative course was complicated by pneumonia that
required outpatient antibiotic treatment. Based on the pathol-
ogy report, postoperative adjuvant chemotherapy was recom-
mended, however, before initiating treatment, restaging ex-
aminations demonstrated metastatic spread to the sternum
and to the liver. A destructive bone lesion was identified in
the midmanubrium, which clearly had not been present be-
fore surgery just a few weeks earlier. Similarly, the appear-
ance of the liver changed dramatically, as he developed liver
function test abnormalities. Chemotherapy with carboplatin
and etoposide resulted in some symptomatic response but
disease progression with metastases was detected by imaging.
The metastatic deposits have not been biopsied to evaluate
which of the tumor components has metastasized.
PATIENTS AND METHODS
Immunohistochemistry
Immunohistochemistry studies were performed using
the Benchmark automated immunohistochemistry equipment
(Ventana Medical System, Tucson, AZ). Prediluted antibod-
ies (Ventana) for TTF-1, chromogranin-A, synaptophysin, and
p53 were used. Cytokeratin 7 (Dako Canada, Mississauga, ON),
CD56 (Zymed Laboratories, South San Francisco, CA) and p63
(Vector Laboratories, Burlingame, CA) were used at 1:2000,
1:100, and 1:50 dilutions. Microwave heat pretreatment was
performed for TTF-1, CD56, synaptophysin, p53, and p63,
while protease and no pretreatment were done for cytokeratin 7
and chromogranin-A, respectively.
DNA Extraction
Tumor and matched normal (noncancerous) lung tissue
samples were obtained at the resection specimen. Individual
tumor samples were cored from specific areas identified from
corresponding sections stained by hematoxylin-eosin and
immunohistochemistry, using the 1.5 mm coring needles of
Tissue Arrayer (Beecher Instruments, Sun Prairie, WI). Tis-
sue cores were obtained for DNA extraction following his-
topathological review of a hematoxylin-and-eosin stained
reference slide. DNA was extracted by a standard phenol:
chloroform protocol. Briefly, deparaffinised tissue cores were
digested overnight with Proteinase K in a buffer containing
10 mM Tris-HCl (pH 8), 1 mM ethylene-diamine-tetra-acetic
acid, 0.5% sodium dodecyl sulfate, and 50 mM NaCl. Sub-
sequent treatment with RNase A was followed by extraction
with a phenol: chloroform mixture, ethanol precipitation, and
resuspension in H2O. DNA concentrations were determined
using an ND-1000 Spectrophotometer (Thermo Scientific,
Wilmington, DE).
Whole Genome Tiling-Path Array CGH
The submegabase resolution tiling-set rearray platform,
comprised of 26,363 overlapping elements, was manufac-
tured at the British Columbia Cancer Agency, as previously
described.8 Separate genome profiles were generated for each
tumor subcomponent, as well as for matched normal tissue.
Briefly, 400 ng of patient DNA and 400 ng of individual male
genomic reference DNA were labeled with cyanine-3 and
cyanine-5 dyes, respectively.9 DNA probes were then pooled
and unincorporated nucleotides were removed with a YM-30
Microcon centrifugation tube (Millipore, Etobicoke, ON).
One hundred micrograms of Cot-1 DNA (Invitrogen, Carls-
bad, CA) was then added and the entire mixture was precip-
itated. This material was then resuspended in a 45 L
cocktail consisting of DIG Easy hybridization solution
(Roche, Mississaga, ON), sheared herring sperm DNA (Sig-
ma-Aldrich, Oakville, ON), and yeast tRNA (Calbiochem,
Mississaga, ON). Probe denaturing and blocking steps were
then carried out at 85°C and 45°C for 10 minutes and for 1
hour respectively. The probe mixture was then applied to the
surface of the SMRTr arrays, coverslips were affixed, and
arrays were incubated at 45°C for 36 to 40 hours. Postincu-
bation, slides underwent five agitating washes in 0.1X saline
sodium citrate, 0.1% sodium dodecyl sulfate at 45°C (each
wash approximately 5 minutes). Rinses with 0.1X sodium
citrate/sodium chloride followed, then drying by centrifuga-
tion. The patient blood DNA sample was also hybridized
against the same individual male genomic reference sample.
Sample Imaging and Data Analysis
Array images were obtained with a charge coupled
device camera system and analyzed with SoftWoRx Tracker
Spot Analysis software (Applied Precision, Issaquah, WA).
Experimental bias due to the array platform and the use of
archived tissue specimens were normalized as previously
described.10,11 SeeGH software was used to plot log2 signal
intensity ratios for each clone on the array against chromo-
somal position.11 Array data were filtered from analysis where
standard deviations between replicate spots were0.1 or signal-
to-noise ratios were 3. Consensus values from replicate anal-
yses using the aCGH-Smooth segmentation algorithm were
used to facilitate definition of genome breakpoint bound-
aries.12 Alterations associated with normal (noncancerous)
tissue were excluded from analysis. Array CGH data have
been made publicly available through the System for Integra-
tive Genomic Microarray Analysis resource (http://sigma.b-
ccrc.ca).13
RESULTS
Tumor Histopathology
The right upper lobe showed a 4.5 cm tumor with at
least three histologically different tumor areas. The predom-
TABLE 1. Immunophenotypes of Tumor Components
Studied by Array CGH
LCNEC AD SC1 SC2
CK7    
TTF-1    
CD56    
Chromogranin-A   /focal 
Synaptophysin    
P63    
P53    
LCNEC, large cell neuroendocrine carcinoma; AD, adenocarcinoma; SC, small
cell; CGH, comparative genomic hybridization.
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FIGURE 2. Comparison of genomic alterations between subcomponents of a combined carcinoma. Each clone on the array
comparative genomic hybridization (CGH) platform is represented at its known chromosomal position by a small dark blue
line. For each array experiment, the signal intensity ratio at each clone is plotted on a log2 scale along the horizontal axis.
Vertical lines show log2 signal intensity ratios from 1.0 (green line) to 1.0 (red line), with unchanged regions falling along
the zero line (purple), green shading marking regions of segmental genomic loss, and red shading marking regions of
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inant component (estimated at 60%) was a large cell carci-
noma with focal trabecular and insular growth pattern (Figure
1A), prominent necrosis (Figure 1B), 10/10 high power
field mitotic count and high percentage areas of tumor cells
showing membranous staining for CD56 (Figure 1C) but
negative staining for chromogranin-A and synaptophysin.
Despite the negative staining for the two latter markers, the
histology and CD56 expression were consistent with a
LCNEC. Approximately 25% of the tumor was a mixed type
moderately differentiated AC with predominantly papillary
and acinar patterns (Figure 1D). The remaining tumor
showed a small call (SC) carcinoma histopathology with
scant cytoplasm, hyperchromatic nuclei, and inconspicuous
nucleoli (Figures 1E, F). In addition, this SC tumor showed
two areas that were distinguished by mainly negative chro-
mogranin-A (Chr-)/CD56 (SC1, Figure 1G) and chr/
CD56 (Figure 1H) immunoprofiles. The immunopheno-
types of the various tumor components are detailed in Table
1. With mediastinal lymph node stations 2R, 4R, 4L, 7, and
11 being negative for malignancy, the tumor was pathologi-
cally staged as pT2N0Mx with prominent lymphatic and
vascular invasion.
Comparative Genomic Profiles
Several segmental DNA changes were detected for the
AC, LCNEC, and each SC component (SC1, SC2) (Table 2,
Supplementary Figure 1). Genome alterations previously asso-
ciated with each lung tumor subtype were observed, including
loss within chromosome 13q that has been associated with
LCNEC tumor and gains within chromosome 5p and losses
encompassing 17p in SCLC (both SC1 and SC2).14–17 Alter-
ations commonly associated with AC included gains within
chromosome 7p (including EGFR) and 17q, as well as loss
within chromosome 3p.18 Also noted were alterations with
different boundaries seen in different tumors, yet encompassing
similar genomic loci. The 1q21.2-q41 region was gained in both
the LCNEC and SCLC components, the former having a seg-
mental gain within the chromosome arm and the other tumors
harboring whole arm gains. Similarly, both the LCNEC and AC
tumors appear to have acquired additional copies of the MYC
oncogene at chromosome 8q24.21, with the former having a
focal amplification in a broader segmental gain spanning this
gene and the latter having a more narrowly defined segmental
gain (Figure 2A).
Identical genomic alterations were seen in multiple
tumors. Specifically, SC1 and SC2 shared multiple whole
chromosome arm changes, including gain of chromosome
arms 1q and 5p, loss of chromosome arm 15q and multiple
intrachromosomal breakpoints. The latter included an identi-
cal breakpoint within chromosome band 13q21.33, with both
tumors showing a loss from 13q11 to q21.33 and a gain from
13q21.33 to q34 (Figure 2B). A fragile site for this specific
genomic region has not been reported previously.19,20 Fur-
FIGURE 2. (Continued) segmental gain. A, Two tumors harbored additional copies of the MYC oncogene: a focal amplifica-
tion spanning this gene was seen for the large cell neuroendocrine carcinoma (LCNEC) component while a lower level seg-
mental gain was seen for the adenocarcinoma (AC) tumor. B, An example of a chromosomal breakpoint shared by SC1 and
SC2. Neither the AC nor LCNEC components exhibited this alteration boundary within 13q21.33. C, The alterations status of
chromosome 20 was different between SC1 and SC2, suggesting ongoing evolution. The first two karyograms show genome
profiles generated by comparison of tumor and reference DNA and are annotated as in parts (A) and (B). The third karyogram
(within the gray box) shows the results of a direct competitive hybridization experiment between SC1 and SC2. As above,
where clones are positioned along the zero line (purple), equivalent copy number between the two samples is inferred. Where
log2 0, it suggests increased DNA copy number for SC2 relative to SC1 (green shading). Where log2 0, the reverse may
be inferred. D, A putative clonal relationship of genetically distinct tumor types in this combined carcinoma. Tumors could
have arisen from different normal airway progenitor cells that might be pleuripotent or lineage-defined.
TABLE 2. Summary of Genome Alterations Identified for each Tumor Component
Tumor Component Shared Alterations Independent Alterations
AC None identified Gain of 4p14-p13, 5p15.33, 6p22.2-21.2, 6q22.33-q23.3, 6q27,
7p21.3-p11.2, 8q24.13-q24.21, 16p13.3-p13.2, 17q12-q25.3,
20q13.2, 20q13.33, 22q11.21-q13.33
Loss of 3p26.3-p22.1, 4p16.1-p15.1, 8p23.1, 9p24.3-q33.1,
11p15.4, 13q33.1-q34
LCNEC None identified Gain of 1q21.2-q41, 8p12-q24.3, 10p15.3-p11.23
Loss of 3q12.3-q21.3, 6q12-q27, 8p23.3-p12, 13q31.1-q34,
16q23.1-q23.3, 17p13.2-p12
SC1 (Chr/CD56) Gain of 1q21.1-q44a, 5p15.33-p12a, 6p25.3-p21.2,
7p22.2-p14.1, 13q21.33-q34
Gain of 16p13.3-p11.2, 20q11.23-q12, 20q13.32-q13.33
Loss of 13q11-q21.33, 15q11.1-q26.3a Loss of 4q31.3, 20p13-p11.21, 17p13.2-p11.2a
SC2 (Chr/CD56) Gain of 1q21.1-q44a, 5p15.33-p12a, 6p25.3-p21.2,
7p22.2-p14.1, 13q21.33-q34
Gain of 20p13-q13.33a
Loss of 13q11-q21.33, 15q11.1-q26.3a Loss of 10q11.1-q26.3, 12q12, 21q11.1-q11.2, 22q11.21-q13.33,
17p13.2-q21.31
a Denotes whole chromosome arm or whole chromosome change.
LCNEC, large cell neuroendocrine carcinoma; SC, small cell; AC, adenocarcinoma.
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thermore, this alteration boundary was not observed in any
tiling-path array CGH profiles for lung cancer cell lines21,22
and has not been reported even at low frequency in other high
resolution analyses of lung tumor genomes.17,18,23–26
Molecular alterations in SC1 and SC2 were not com-
pletely identical, as differences between these tumors were
observed at other genomic loci. Analysis of both individual
profiles for SC1 (Chr/CD56) and SC2 (Chr/CD56)
and a direct comparative hybridization between these two
tumors confirmed a 20p deletion specific to the SC1 tumor
(Figure 2C). Gene copy number changes at CHGA (chro-
mogranin-A) or NCAM1 (CD56) were not observed for either
SCLC subcomponent.
DISCUSSION
Many of the genome alterations observed in this case
matched previously described changes associated with spe-
cific lung cancer histologies. Those genes altered in multiple
tumors from the same individual may represent changes that
are essential to lung tumorigenesis, regardless of disease
subtype. Where alterations with different boundaries spanned
the same genomic regions, independent activation of these
regions can be inferred. This suggests that genes in these
regions may be necessary factors for lung cancer initiation in
general. In this case, gain at chromosome 1q21.2-q41 in the
LCNEC, SC1, and SC2 components suggested independent
activation of several genes, including the putative oncogene
KIF14, which has previously been implicated in a variety of
cancer types.27,28 TheMYC oncogene appears to have undergone
similar independent activation in the AC and LCNEC tumors.
The fine mapping of alteration boundaries afforded by our
high-resolution genome analysis also revealed identical alter-
ations for the SCLC components of this case. Given the precise
similarity of these alteration boundaries, their lack of association
with previously described genome fragile sites, and their rarity in
previously undertaken genome analyses of lung cancer cells, it is
quite possible that the identical chromosomal rearrangements
found in these tumors represent an early evolution from a
common tumor stem/progenitor cell. Changes such as deletion
of chromosome 20p in SC1 but not in SC2 would then be
indicative of subsequent clonal divergence. While morphologic
features are limited for evaluating the relationship between SC1
and SC2, the genomic data are salient with respect to confirming
the clonal relationship between these lesions.
Taken together, our results suggest that this patient had
multiple primary tumors with divergent clonal evolution.
Based on alterations seen in SC1 and SC2 and the fact that the
LCNEC and AC components harbored several alterations not
observed in the other tumors, we deduced a clonal relation-
ship between tumors that is depicted in Figure 2D. This case
demonstrates the potential utility of using DNA alteration
boundaries as a means of classifying tumor relationships.
Ultimately, integration of our data with global analysis of
DNA sequence changes or epigenetic alterations for these
same tumors could yield even further insights into the clonal
relationship between these tumors.29,30 With standardized
approaches to sample handling and data analysis, high reso-
lution genome profiling technologies may be reasonably
adapted to a clinical setting where they could have a signif-
icant impact on diagnosis and possibly on patient care.
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Supplementary Figure 1. Tiling-path array comparative genomic hybridization (CGH) karyograms for all combined carci-
noma components described in this case report. Karyograms are annotated as in Figure 2. A, Adenocarcinoma component
(AC). B, Small cell lung carcinoma (SCLC) component with Chr/CD56 staining (SC1). C, SCLC component with Chr/
CD56 staining (SC2). D, Large cell neuroendocrine carcinoma component (LCNEC). E, Normal (noncancerous) tissue. F, Di-
rect competitive hybridization between SC1 and SC2 components (annotated as described for Figure 2C).
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Supplementary Figure 1. (Continued).
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Supplementary Figure 1. (Continued).
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Supplementary Figure 1. (Continued).
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Supplementary Figure 1. (Continued).
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Supplementary Figure 1. (Continued).
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